Statistics

Total Visits

Views
Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer48

Select a period of time:

Number of views in the range

Views
Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer17

Views

Views
May 20250
June 20250
July 20259
August 20252
September 20255
October 20251
November 20250
Download CSV file
 untranslated
 untranslated

Top country views

Views
United States8
Brazil5
South Africa2
Ecuador1
Jamaica1
 

Top cities views

Views
São Paulo3
Arlington1
Cape Town1
Concord1
Dallas1
Houston1
Manta1
Montego Bay1
Niterói1
Pretoria1